NYSEAMERICAN:AST - Asterias Biotherapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.7389 -0.02 (-2.64 %) (As of 01/20/2019 04:00 PM ET)Previous Close$0.7389Today's Range$0.73 - $0.8252-Week Range$0.51 - $2.45Volume104,128 shsAverage Volume112,148 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Receive AST News and Ratings via Email Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:AST Previous SymbolNYSEMKT:AST CUSIPN/A Webasteriasbiotherapeutics.com Phone+1-510-4563805Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees31 Outstanding Shares55,659,000Market Cap$0.00 OptionableOptionable Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions What is Asterias Biotherapeutics' stock symbol? Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST." How were Asterias Biotherapeutics' earnings last quarter? Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its quarterly earnings data on Friday, November, 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. The biotechnology company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. View Asterias Biotherapeutics' Earnings History. When is Asterias Biotherapeutics' next earnings date? Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Asterias Biotherapeutics. What price target have analysts set for AST? 3 brokerages have issued 1 year price objectives for Asterias Biotherapeutics' stock. Their predictions range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' stock price to reach $8.50 in the next year. This suggests a possible upside of 1,050.4% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics. What is the consensus analysts' recommendation for Asterias Biotherapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics. What are Wall Street analysts saying about Asterias Biotherapeutics stock? Here are some recent quotes from research analysts about Asterias Biotherapeutics stock: 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (1/18/2019) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of- the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer." (9/5/2018) Has Asterias Biotherapeutics been receiving favorable news coverage? Media coverage about AST stock has trended neutral on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Asterias Biotherapeutics earned a daily sentiment score of 0.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Are investors shorting Asterias Biotherapeutics? Asterias Biotherapeutics saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 344,134 shares, a decline of 43.8% from the December 14th total of 612,508 shares. Based on an average trading volume of 352,273 shares, the short-interest ratio is presently 1.0 days. Approximately 1.0% of the company's stock are sold short. View Asterias Biotherapeutics' Current Options Chain. Who are some of Asterias Biotherapeutics' key competitors? Some companies that are related to Asterias Biotherapeutics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB). Who are Asterias Biotherapeutics' key executives? Asterias Biotherapeutics' management team includes the folowing people: Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)Dr. Edward D. Wirth III, Chief Medical Officer (Age 53)Dr. Katharine E. Spink, Consultant (Age 44)Mr. Stephen L. Cartt, Advisor & Director (Age 55)Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42) How do I buy shares of Asterias Biotherapeutics? Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Asterias Biotherapeutics' stock price today? One share of AST stock can currently be purchased for approximately $0.7389. What is Asterias Biotherapeutics' official website? The official website for Asterias Biotherapeutics is http://asteriasbiotherapeutics.com. How can I contact Asterias Biotherapeutics? Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805. MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 116 (Vote Outperform)Underperform Votes: 101 (Vote Underperform)Total Votes: 217MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: How are institutional investors different from individual investors?